Cancer Archives

News and Trends 3 May 2017

New Immuno-oncology Biotech Gets a €20M Series A Funding Boost

Imcheck Therapeutics from Marseille has just completed a €20M Series A funding round, backed by big investors like the Boehringer Ingelheim Venture Fund (BIVF). The French biotech Imcheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute (IPC) in Marseille and is developing next-generation immunomodulatory antibodies for the treatment of cancer and autoimmune diseases. […]

May 3, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 3 May 2017

Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?

As immunotherapies are moving from large academic centers to clinics across the world, doctors are realizing that releasing the breaks of the immune system comes with serious risks – and that research on its adverse effects is lagging behind. This week, AstraZeneca’s anti-PD-L1 antibody durvalumab received FDA approval to treat patients with metastatic urothelial carcinoma, making […]

May 3, 2017 - 4 minutesmins - By Melanie De Almeida

News and Trends 2 May 2017

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies, based on engineering donor-derived allogeneic T cells. Despite a recent public dispute with its key rival Cellectis regarding the validity of Celyad’s US patents, Novartis has now entered a non-exclusive […]

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 26 Apr 2017

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […]

April 26, 2017 - 1 minutemin - By Melanie De Almeida

News and Trends 20 Apr 2017

Norway Brings Another Cancer Vaccine to the Clinic

Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell division and are a key driver of cancer progression and treatment resistance. The Norwegian biotech Targovax is developing peptide-based anti-cancer vaccines targeting these mutations found […]

April 20, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 20 Apr 2017

Which EU Immuno-Oncology Company are you Cheering for?

Immuno-oncology represents a huge breakthrough towards the search for a cancer cure. Biotechs all around Europe are developing innovative ways of helping our own immune system fight tumors, which one do you think is doing it best? The field of immuno-oncology is overcrowded, and there’s plenty of companies pushing to make their cutting-edge technology a […]

April 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 19 Apr 2017

Researchers Unmask How a New Diet can help Cure Cancer

Researchers from the University of Glasgow and the Cancer Research UK Beatson Institute found that cancer cells are dependent on specific amino acids. In a new study published today in Nature, researchers found that removing two non-essential amino acids – serine and glycine – from the diet of mice slowed the development of lymphoma and intestinal […]

April 19, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 19 Apr 2017

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Novartis and Kite have been in a tight race to bring the first CAR-T therapy to market: Novartis has staked out acute lymphoblastic leukemia (ALL) while Kite has gone for DLBCL. With this “tacit endorsement,” Novartis is encroaching on […]

April 19, 2017 - 3 minutesmins - By Evelyn Warner

Startup Scout 14 Apr 2017

This Norwegian Biotech Aims to Unlock the Full Potential of Cancer Drugs

This week we visited the Norwegian PCI Biotech. Based in Oslo, this company has developed a light-sensitive technology, which allows to activate cancer drugs at specific sites of the body by targeted illumination. Mission: PCI Biotech focuses on the development of new therapies for the treatment of cancer based on its photochemical internalisation (PCI) technology. The PCI technology consists of a photosensitising […]

April 14, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 13 Apr 2017

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Transgene Pexa Vec Oncolytic Virus Vaccine

News and Trends 13 Apr 2017

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […]

April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Apr 2017

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

New Immuno-oncology Biotech Gets a €20M Series A Funding Boost

Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Norway Brings Another Cancer Vaccine to the Clinic

Which EU Immuno-Oncology Company are you Cheering for?

Researchers Unmask How a New Diet can help Cure Cancer

UPDATE: Novartis broadens CAR-T onslaught with FDA endorsement

This Norwegian Biotech Aims to Unlock the Full Potential of Cancer Drugs

Next-Gen Cancer Antibody Technology from Germany enters the Clinic

French Oncolytic Virus Vaccine for Breast Cancer enters Phase II

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!